Inflammation can promote or inhibit cancer progression. In this study we have addressed the role of the proinflammatory cytokine thymic stromal lymphopoietin (TSLP) during skin carcinogenesis. Using conditional loss-and gain-of-function mouse models for Notch and Wnt signaling, respectively, we demonstrate that TSLP-mediated inflammation protects against cutaneous carcinogenesis by acting directly on CD4 and CD8 T cells. Genetic ablation of TSLP receptor (TSLPR) perturbs T-cell-mediated protection and results in the accumulation of CD11b + Gr1 + myeloid cells. These promote tumor growth by secreting Wnt ligands and augmenting b-catenin signaling in the neighboring epithelium. Epithelial specific ablation of b-catenin prevents both carcinogenesis and the accumulation of CD11b + Gr1 + myeloid cells, suggesting tumor cells initiate a feed-forward loop that induces protumorigenic inflammation.
INTRODUCTION
For many years cancer has been regarded predominantly as a cell autonomous process in which genetically transformed cells propagate the development of malignant neoplasms. However, today it is well established that tumor progression requires complex interactions between neoplastic cells and the host-derived stroma, including tumor-associated fibroblasts, niche-defining cells, and vasculature. Of critical importance is also the relationship between the tumor and the host immune system. Originally, tumor-infiltrating immune cells were thought to reflect the attempts of the immune system to eliminate cancer cells. However, today a large body of evidence indicates that malignant neoplasms can induce qualitatively distinct types of inflammation that are protumorigenic (Coussens and Werb, 2002; Hanahan and Weinberg, 2011) .
Cancer-associated inflammation frequently exhibits profiles that promote both immune evasion and the growth of malignant cells. Tumors can evade T-cell-mediated clearance by skewing the acquired immune response from cytotoxic Th1 to permissive Th2 profiles (Aspord et al., 2007) or by inducing immunosuppressive regulatory T cells (Quezada et al., 2011) . Tumors can also co-opt cells of the innate immune system to become constituents of the protumorigenic stroma. Notably, cells of the myeloid lineage, such as macrophages (Allavena et al., 2008) and neutrophils (Fridlender et al., 2009) can promote tumor growth by a variety of mechanisms, depending on their differentiation status. Furthermore, poorly defined immature myeloid cells can foster tumor growth directly (Kowanetz et al., 2010; Qian et al., 2011; Yang et al., 2011) or by acting as myeloid-derived suppressor cells (Gabrilovich and Nagaraj, 2009) .
These data demonstrate that tumor cells modulate both acquired and innate arms of the immune system to form an integral component of the tumor stroma. The molecular basis for such immunomodulatory roles, however, is poorly defined,
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and it is unclear to what extent oncogenes/tumor suppressors influence tumor development by such indirect mechanisms.
Mutations in the Notch signaling pathway are associated with a variety of human cancers and indicate that Notch can function as either a tumor suppressor or an oncogene (Weng and Aster, 2004) . In the skin, conditional inactivation of Notch1 in the mouse epidermis results in the development of basal/ squamous cell carcinoma after chemically induced carcinogenesis (Demehri et al., 2009; Nicolas et al., 2003; Proweller et al., 2006) , suggesting that Notch functions as a tumor suppressor in this tissue. In accordance, loss-of-function mutations in human Notch receptors correlate with cutaneous and lung squamous cell carcinoma (Agrawal et al., 2011; Stransky et al., 2011; Wang et al., 2011) .
Factors acting downstream of Notch with respect to epithelial malignancies remain to be fully elucidated. However, deletion of Notch1 in the murine epidermis leads to elevated levels of activated b-catenin (Nicolas et al., 2003) , which has been shown to induce skin tumor formation and regulate the maintenance of CD34
+ cancer stem cells (Gat et al., 1998; Malanchi et al., 2008) . The tumor suppressor activity of Notch signaling in the skin may therefore at least in part be due to negative regulation of the Wnt/b-catenin pathway. Whether b-catenin accumulation is due to cell autonomous deregulation or is mediated by crosstalk between different cell populations is unclear, although there is evidence for both mechanisms (Devgan et al., 2005; Kwon et al., 2011; Sanders et al., 2009) . Conditional inactivation of both Notch1 and Notch2 in the murine epidermis results in a chronic inflammatory condition resembling a severe form of atopic dermatitis (AD) that occurs as a consequence of elevated TSLP expression by keratinocytes (Demehri et al., 2008; Dumortier et al., 2010) . This cytokine has been shown to affect a variety of cell types in the immune system and as such is believed to play a role in allergic disorders, including AD and asthma (Ziegler, 2010) . Interestingly, elevated TSLP has also been associated with progression of various epithelial malignancies, including breast and pancreatic cancer (De Monte et al., 2011; Olkhanud et al., 2011; Pedroza-Gonzalez et al., 2011) . In light of this, it is intriguing that loss of Notch in the skin results in increased tumor susceptibility and elevated expression of TSLP. It is presently unclear to what extent these processes are linked, although elucidation of how they interact may provide insight into how inflammation can exert either anti-or protumorigenic effects.
In this study, we have delineated the role of TSLP-mediated inflammation during skin tumorigenesis by using loss-and gain-of-function approaches for Notch and Wnt signaling, respectively. Figure S1A ). The hyperproliferative cystic structures in N1N2K5 TSLPR mice frequently extended deep into the underlying connective tissue of the dermis and were often visible on the surface of the skin ( Figures 1A and S1B ). Pathological analysis classified these hyperproliferative cysts as dysplastic lesions resembling keratoacanthomas, relatively low-grade hair follicle malignancies that can progress to invasive squamous cell carcinomas. The severity of the phenotype in N1N2K5 TSLPR animals was reflected in survival rates, as these mutants died by day 60 post-gene-inactivation ( Figure 1D ), most likely because of complications resulting from barrier dysfunction and tumor burden (data not shown). These data indicate that TSLPR signaling prevents tumor formation in Notch-deficient skin. In support of this, injection of N1N2K5 mice with TSLP-neutralizing antibodies resulted in tumor development in 60% of animals ( Figure S1D ), thus confirming the tumor protective function of TSLP-TSLPR interactions.
RESULTS

Loss of TSLP Receptor Signaling in Notch Mutant
The Tumor Protective Effect of TSLP Is Mediated by Hematopoietic Cells
The TSLPR is expressed by a variety of hematopoietic cells, including T, B, and dendritic cells. We therefore speculated that elevated levels of TSLP may elicit tumor protective immune responses. To confirm this, we generated bone marrow (BM) chimeras in which CD45.2 N1N2K5 hosts were reconstituted with CD45.1 Tslpr À/À BM prior to Notch inactivation. The reciprocal experiment was also performed, in which CD45.1 Tslpr
BM was used to reconstitute CD45.2 N1N2K5 TSLPR mice (Figure 2A) . In the former, TSLPR À/À / N1N2K5 chimeras developed hyperproliferative dermal cysts, resembling the tumors observed in N1N2K5 TSLPR mice upon ablation of Notch signaling ( Figure 2B ). Conversely, N1N2K5 TSLPR mice reconstituted with Tslpr +/+ BM were protected from tumor formation and instead developed the AD-like disease that occurs in N1N2K5 animals ( Figure 2B ). These data confirm that TSLPR signaling elicits antitumor responses in hematopoietic cells.
Ablation of TSLPR Signaling Alters the Inflammatory Microenvironment in Notch-Deficient Skin
The impaired antitumor immune response elicited in N1N2K5 TSLPR mice could result from either a decreased dermal inflammatory response and/or an altered inflammatory profile.
To discriminate between these possibilities, we analyzed the inflammatory cells present in the dermis of both N1N2K5 and N1N2K5 TSLPR mice by flow cytometry.
We noted that during the earlier stages subsequent to Notch inactivation, the inflammatory response in N1N2K5 TSLPR mice was reduced compared to N1N2K5 mutants (data not shown). However, once the macroscopic phenotype was highly overt at 4-5 weeks after Notch ablation, the proportion of dermal CD45 + cells in both N1N2K5 and N1N2K5 TSLPR mice was on average 5-fold higher compared to normal littermate controls ( Figure 2C ). Thus, the inflammatory response in N1N2K5 and N1N2K5 TSLPR mice was quantitatively equivalent at the phenotypic endpoint. Detailed phenotypic analysis of the dermal inflammatory infiltrates revealed several changes between N1N2K5 and N1N2K5 TSLPR mice, including alterations in the proportions of CD117 + mast cells and B220 + B cells ( Figure 2D ). However, the most striking differences were apparent in the T and myeloid cell compartments. In N1N2K5 animals, the proportion of CD4 + and CD8 + T cells was 12.7% and 10.4%, respectively, whereas in N1N2K5 TSLPR mice, the proportions were reduced on average to 1.8% and 1.1% ( Figure 2D ). In addition, CD11b + Gr1 + myeloid cells constituted just 7.2% of dermal CD45 + cells in N1N2K5 mice, whereas this population increased dramatically to 36.7% upon ablation of TSLPR ( Figure 2D ).
Collectively, these data demonstrate that loss of TSLPR signaling in Notch-deficient epidermis results in reduced proportions of CD4 + and CD8 + T cells and increased infiltration of Figure S1 .
TSLPR Signaling in T Cells Mediates Protection against Tumor Formation
The observation that specific populations of dermal inflammatory cells are altered quantitatively upon ablation of TSLPR signaling suggests that the cells responsible for mediating tumor protection in response to TSLP are likely to be within these compartments. Therefore, to functionally assess the role that specific cell types play in TSLP-mediated tumor protection, lethally irradiated N1N2K5 mice were reconstituted with Tslpr +/+ BM derived from different gene targeted mice lacking specific hematopoietic cell types ( Figure 2E ). In this system, the development of tumors after Notch inactivation is a direct consequence of loss of a specific hematopoietic population.
We initially determined the functional contribution of lymphoid populations by reconstituting N1N2K5 mice with Rag2 À/À ;gc
and Rag2 À/À BM. In both cases, more than 90% of reconstituted N1N2K5 mice developed tumors, indicating that the protective cell type resided within the T or B cell compartment, not the NK cell population (Figures 2F and S2A) . Consistent with this, 78% of the mice in which NK cells were depleted by injection of PK1.36 monoclonal antibody remained tumor free, and those mice that did develop tumors presented only mild lesions (Figure S2B) . To determine if B cells were required for tumor protection, we reconstituted N1N2K5 mice with Jh À/À BM. In this experiment, 83% of mice were resistant to tumor formation, indicating that B cells do not mediate TSLPR-dependent tumor protection and therefore suggesting that the critical cell type resides within the T cell compartment (Figures 2F and S2A) . In support of this, antibody-mediated depletion of CD4 + and CD8 + T cells resulted in tumor development in 83% of N1N2K5 mice ( Figure S2C ). To establish the role of T cells conclusively, we reconstituted N1N2K5 mice with Cd4 À/À and Cd8a À/À BM.
In this setting, the majority of mice reconstituted with Cd4
BM were resistant to tumor formation (73%), whereas 74% of Cd8a À/À / N1N2K5 chimeras developed severe tumors ( Figures 2F and S2A ). Taken together, these data demonstrate Figure 3A ; Figure S3A ). When CD8 + or CD4 + T cells were transferred alone, the proportion of recipients exhibiting tumor resistance was 65% and 90%, respectively ( Figure 3B ). Figure 3C ). The highest level of protection was observed when CD4 + and CD8 + T cells were administered together, as recipients in these cases exhibited complete protection from tumor development (Figure 3B) . Importantly, tumor protection did not occur as a consequence of inefficient gene inactivation or counterselection of Notch-deficient epidermal cells ( Figures S3C and S3D ). The finding that the adoptive transfer of WT T cells can prevent tumor formation in N1N2K5 TSLPR mice indicates that T cells respond directly to TSLP and do not act in response to another TSLP responsive cell type. Consistent with this, phosphoflow cytometric analysis of pSTAT5 expression, which acts downstream of TSLPR ligation, revealed that only dermal CD4 + and CD8 + T cells from N1N2K5 mice are pSTAT5 + ( Figures 3D and  S3E ). Interestingly, TSLPR signaling does not appear to be required for T cell migration in vitro ( Figure S3F ), and thus it seems likely that its tumor-protective effect is mediated via increased T cell survival/proliferation and/or activation.
Finally, to determine if TSLP-responsive T cells could elicit protection against preformed tumors, we adoptively transferred CD4 + and CD8 + T cells into N1N2K5 TSLPR mice 2 weeks post-gene-inactivation and assayed tumor development (Figure 3E) Figure 4A ). Depletion of Gr1 + cells was confirmed by flow cytometric analysis of both peripheral blood and dermal infiltrates ( Figure 4B and data not shown), and tumor progression was assessed by histology. As expected, mice receiving isotype control antibody developed large cystic tumors lined by hyperproliferative epithelial cells ( Figures 4C  and 4D ). In contrast, mice in which Gr1 + cells were depleted developed smaller cysts that were predominantly lined by epithelial cells 1-2 cell layers thick, and thus resembled the phenotype observed in N1N2K5 mice ( Figures 4C and 4D) . The above data indicated that CD11b + Gr1 + myeloid cells perform a functional role in promoting tumor development. This observation may reflect myeloid-derived suppressor cell activity, in which antitumor T cell responses are suppressed, or may be due to the promotion of tumor growth in a more direct manner. To distinguish between these possibilities, we isolated CD11b + Gr1 + myeloid cells from the tumor-associated microenvironment of N1N2K5 TSLPR mice and assessed their ability to suppress T cell activation in vitro. We could not detect any effect of CD11b + Gr1 + myeloid cells on the proliferation of either CD4 + or CD8 + T cells ( Figure 4E ). Accordingly, depletion of CD11b + Gr1 + cells did not result in an increase of dermal T cells in N1N2K5 TSLPR mice (Table S1 ). These data therefore suggest that the CD11b + Gr1 + population does not perturb T cell responses but rather promotes tumor growth directly.
Tumor Formation in the Absence of TSLPR Signaling Is b-Catenin Dependent
The macroscopic phenotype presented in N1N2K5 TSLPR mice is reminiscent of extracolonic manifestations presented in patients with familial adenomatous polyposis (FAP), in which loss-of-function mutations in the APC gene result in constitutive activation of the Wnt/b-catenin pathway (Jagelman, 1991) . Elevated b-catenin-mediated signaling is also implicated in a variety of skin cancers (Gat et al., 1998; Malanchi et al., 2008) . The link between Wnt/b-catenin signaling and cancer therefore prompted us to investigate the status of b-catenin in N1N2K5 TSLPR mice.
Immunohistochemistry (IHC) for active b-catenin was performed on skin sections from N1N2K5, N1N2K5 TSLPR, and N1N2 TSLPR control mice. In N1N2K5 TSLPR mutants, active b-catenin was present in the majority of hyperproliferative cysts, in contrast to N1N2K5 mice, where it was largely absent ( Figure 5A ). These data suggest a role for b-catenin in the development and/or maintenance of skin tumors in these animals.
To investigate whether b-catenin is functionally required for tumor development, we generated Figures  S4A and S4B) . Strikingly, ablation of b-catenin prevented the formation of cystic tumors in N1N2bcatK5 TSLPR mice, establishing that tumor development in these animals is b-catenin dependent ( Figure 5B ). Flow cytometric analysis of dermal infiltrates in N1N2bcatK5 TSLPR mice revealed increased infiltration of CD45 + cells compared to littermate control animals, cells/well), and T cell numbers were reduced appropriately to adjust the T cell:myeloid cell ratio. BrdU incorporation was determined by measuring absorbance after 72 hr of coculture. Data represents the results of three independent experiments (mean ± SD). See also Table S1 .
confirming that in this context epidermal deletion of Notch continued to elicit a chronic inflammatory response ( Figure S4C ). Consistent with the absence of TSLPR, CD4 + and CD8 + T cells represented less than 3% of dermal CD45 + cells ( Figure 5C ).
Importantly, serum levels of TSLP remained elevated despite the loss of b-catenin ( Figure S4D) . Interestingly, the accumulation of dermal CD11b + Gr1 + myeloid cells was impaired in N1N2bcatK5 TSLPR mice ( Figure 5D ), indicating that the recruitment and/or development of this population is independent of TSLP but dependent on epithelial-specific Wnt/b-catenin signaling.
CD11b + Gr1 + Myeloid Cells Promote Tumor Development by Provision of Wnt Ligands
Having established that b-catenin signaling is required for cutaneous tumor development in N1N2K5 TSLPR mice, we next frequently located in close proximity to epithelial tumor cells (Figure 6C) . In N1N2K5 dermis, Gr1 + cells were only rarely detected, although those that were present were also WNT3A + ( Figure 6C and data not shown). We also analyzed WNT3a expression by western blot in tumor-bearing and non-tumor-bearing regions of N1N2K5 TSLPR skin and correlated this data with the proportions of CD11b + Gr1 + myeloid cells present. Consistent with our previous observations, the highest levels of WNT3a expression were detected in tumor-bearing regions of skin containing high proportions of CD11b + Gr1 + myeloid cells ( Figure 6D ; Figures   S5A-S5C ). We also observed WNT3A expression in cystic epithelial cells in both N1N2K5 and N1N2K5 TSLPR skin (Figure 6C ; Figure S5B ), indicating that CD11b
are not the exclusive source of this protein.
These data suggest that the elevated Wnt/b-catenin signaling observed in N1N2K5 TSLPR skin tumors is at least in part mediated by CD11b + Gr1 + myeloid cells. To explore this possibility further, we performed a coculture assay using a Tcf-luciferase reporter cell line (Tcf-Luc) in conjunction with myeloid cells and/or fibroblasts isolated from tumor-bearing N1N2K5 TSLPR skin. Coculture with CD11b + Gr1 + cells or fibroblasts alone did not induce luciferase activity in the Tcf-Luc cells. However, when used in combination, CD11b + Gr1 + cells and tumor fibroblasts induced a significant 2.5-fold increase in luciferase activity compared to Tcf-Luc cells cultured alone ( Figure 6E ), indicating that these cells have the functional capacity to induce Wnt/b-catenin signaling in neighboring cells. The requirement of tumor-associated fibroblasts likely reflects the expression of potentiating factors by these cells, as we observed markedly increased expression of the Wnt-potentiator Periostin (POSTN) (Malanchi et al., 2012) in the stroma of N1N2K5 TSLPR dermis ( Figure S5D ). Collectively, these data indicate that the accumulation of CD11b + Gr1 + myeloid cells in N1N2K5 TSLPR mice results in promotion of tumor growth by increased provision of Wnt ligands. In support of this conclusion, depletion of CD11b + Gr1 + cells from the dermis of N1N2K5 TSLPR mice using the RB6.8C5 antibody results in reduced nuclear b-catenin staining in epidermal cysts ( Figure S5E ).
TSLPR Signaling Mediates Tumor Protection in Notch-Independent Skin Cancers
We next sought to determine if TSLP signaling could mediate tumor protection in other models of skin cancer in which Notch expression/signaling is maintained in the epidermis. To this end, we utilized Ctnnb1 lox(ex3) ;K5Cre ERT mice (hereafter bcatD3K5), in which constitutively active b-catenin can be induced in the epidermis by conditionally deleting exon3 of the b-catenin gene (Harada et al., 1999) . In this model, activation of b-catenin results in the formation of hair-follicle-derived tumors over a period of several months (Gat et al., 1998) . We subsequently generated bcatD3K5 mice lacking TSLPR (bcatD3K5 TSLPR) and induced expression of the dominant active mutant of b-catenin. In agreement with previous reports, bcatD3K5 mice developed mild skin phenotypes at 75 days post-gene-induction (Gat et al., 1998) , presenting as cystic hair-follicle-derived tumors ( Figure 7A ). In contrast, bcatD3K5 TSLPR mutants developed overtly more severe phenotypes within 25 days of b-catenin induction, exhibiting extensive hair loss and thickening of the skin ( Figure 7A ). When analyzed histologically, cystic tumors were prevalent and were significantly larger than those observed in bcatD3K5 mice ( Figures 7A  and 7B ), which at this time point had not developed a severe skin phenotype. The difference in phenotypic severity between the TSLPR-deficient and competent mice was reflected in survival rates, with 80% of bcatD3K5 TSLPR animals succumbing within 30 days of b-catenin induction. By contrast, all bcatD3K5 mice survived beyond 60 days ( Figure S6A ). Importantly, TSLP serum levels were increased in both bcatD3K5 and bcatD3K5 TSLPR animals compared to littermate controls ( Figure 7C ). Moreover, analysis of dermal inflammatory cells revealed that CD4 + and CD8 + T cells were significantly reduced in Tslpr À/À compared to Tslpr +/+ control mutants ( Figure 7D ), supporting the hypothesis that TSLP mediates protection from cutaneous tumors by promoting T-cell-mediated immunity.
Interestingly, we also observed accumulating CD11b + Gr1 + populations in the cutaneous tumors arising in bcatD3K5 TSLPR mice ( Figure 7D ). In this system b-catenin signaling is activated in the epithelium autonomously and thus the effects of Wntdriven tumorigenesis should be independent of stromal derived ligands. To confirm this, we depleted CD11b + Gr1 + cells in bcatD3K5 TSLPR mice by intraperitoneal injection of RB6.8C5 and assessed tumor development upon gene activation. Consistent with our hypothesis, tumor development in these animals was not adversely affected by the depletion of Gr1 + myeloid cells ( Figures S6B-S6D ). Taken together, these results suggest that TSLPRmediated inflammation protects against different forms of cutaneous tumors. In support of this conclusion, the accompanying 
Gr1
+ Myeloid Cells Promote Tumor Development by Secreting Wnt Ligands (A and B) Real-time PCR analysis for Wnt ligand expression performed on RNA isolated from whole-tumor-bearing N1N2K5 TSLPR skin (A) or specific cell populations isolated from the tumor microenvironment (B). In (A) gene expression is expressed relative to whole skin isolated from N1N2 TSLPR controls. In (B) gene expression is expressed relative to tumor-associated fibroblasts. Data represent the mean ± SD of three independent experiments. (C) IF staining for Gr1, CD45, and WNT3a expression in the dermis of N1N2K5 and N1N2K5 TSLPR mice. Asterisks demarcate cyst lumen; dotted lines mark the border between the cystic epithelium and the surrounding dermis. The image shown for N1N2K5 skin displays a region with extensive CD45 staining to demonstrate the low proportions of Gr1 + cells. Scale bars: 100 mm.
(D) Western blot analysis of WNT3a expression in whole-skin extracts from nontumor and tumor-bearing regions of N1N2K5 TSLPR mice. Tubulin was used as loading control; lanes shown are cropped from the same blot. The original blot is shown in Figure S5C . (E) CD11b + Gr1 + and CD11b + Gr1 -myeloid cells were isolated from tumor-bearing skin of N1N2K5 TSLPR mice and cocultured with 293T cells expressing a Tcf-luciferase reporter (Tcf-Luc), with or without fibroblasts isolated from N1N2K5 TSLPR tumor-bearing skin (Tum Fibr) or WT dermis (WT Fibr). Luciferase activity was measured 36 hr after coculture (mean ± SD). See also Figure S5 . See also Figure S6 .
Cancer Cell
TSLP Promotes Antitumor Inflammation in the Skin manuscript by Demehri et al. (2012) in this issue of Cancer Cell also demonstrates that TSLP-dependent immune responses can protect against DMBA/TPA-induced tumors in a wild-type background. Importantly, this model is independent of any pre-existing genetic aberrations.
DISCUSSION
In this study, we have revealed a tumor protective role for the cytokine TSLP during cutaneous skin cancer development. This effect is primarily mediated by direct signaling on dermal CD4 + and CD8 + T cells via the TSLPR, which prevents the growth of b-catenin-dependent hair follicle tumors in Notch lossof-function and b-catenin gain-of-function mouse models. Loss of TSLPR responsive T cells results in tumor development and is accompanied by the induction of protumorigenic inflammation, which augments Wnt/b-catenin signaling. These findings reveal a tumor-protective role for TSLP and demonstrate how acquired and innate arms of the immune system can mediate pro-and antitumor effects. This in turn may have broader implications with respect to the role of inflammation in other epithelial malignancies. . However, it has been shown that TSLP can promote the development of cytotoxic CD8 + T cells by inducing the differentiation of cytolytic effectors that express IL-5 and IL-13 (Soumelis and Liu, 2004) . We also find that expression levels of IL-5 and IL-13 are elevated in N1N2K5 dermis (Dumortier et al., 2010) , suggesting that TSLP induces a similar cytotoxic state in this model. In addition, it appears likely that TSLP acts to maintain dermal T cells, as their proportions are significantly reduced upon TSLPR ablation. This is unlikely to be a consequence of impaired homing as Transwell migration studies indicate that Tslpr À/À T cells show normal migration ( Figure S3F ), consistent with a previous report (He et al., 2008) . Activation of dermal T cells is also unaffected by loss of TSLPR (data not shown), suggesting that activation-associated proliferation is not perturbed. It is therefore likely that TSLP signaling promotes T cell survival by acting directly on CD4 + and CD8 + T lymphocytes, as demonstrated by earlier studies (Al-Shami et al., 2005; Rochman et al., 2007; Rochman and Leonard, 2008) .
TSLP and T-Cell-Mediated Tumor Protection
Regardless of the precise mechanism, the data presented here indicate that the tumor-protective role of TSLP is primarily mediated by a direct effect on dermal T cells. In support of this conclusion, the accompanying manuscript by Demehri et al. (2012) (Beck et al., 2011) . We also observe expanded populations of immature CD34 + epithelial cells in the tumors arising in N1N2K5 TSLPR mice (data not shown), suggesting similar mechanisms may be operating in the models used in this study. Finally, it is possible that loss of TSLP-mediated immune responses results in increased loads of pathogenic organisms that may induce protumorigenic inflammation, as has been suggested by the link between specific infections and carcinogenesis (Parkin, 2006) .
Wnt-Dependent Tumor Promotion by CD11b
+ Gr1 +
Myeloid Cells
The tumor-promoting role of CD11b + Gr1 + myeloid cells has been reported previously by a variety of studies (Kowanetz et al., 2010; Qian et al., 2011; Rodriguez and Ochoa, 2008) . Here, we demonstrate that these cells can exert this effect by augmenting Wnt/b-catenin signaling in neighboring epithelial cells via the secretion of Wnt ligands. The ability of CD11b + Gr1 + myeloid cells to induce Wnt/ b-catenin signaling is dependent on tumor-associated fibroblasts, which probably reflects increased expression of the Wnt potentiator POSTN. This suggests that the dermal stroma in these mice is primed to facilitate the protumorigenic function of CD11b + Gr1 + myeloid cells. Because the recruitment of CD11b + Gr1 + cells is itself dependent on elevated b-catenin expression in the epidermis, it is likely that Wnt pathway activation is an early event during tumor progression in the models described here. Indeed, loss of Notch receptors can increase levels of nuclear b-catenin in a cell autonomous manner (Devgan et al., 2005; Kwon et al., 2011) . Therefore, we suggest that once recruited to the tumor stroma, myeloid populations can augment the Wnt signaling cascade and drive tumor growth. In this way, the epithelial population that initiates cancer development establishes a feed-forward loop that favors tumor progression.
Context-Dependent Role of TSLP during Cancer Development
The central theme of this study is the tumor-protective effect of TSLP during cutaneous cancer development. This is in contrast to previous reports that find TSLP can promote tumor growth and metastasis in mouse models of breast and pancreatic cancer (De Monte et al., 2011; Olkhanud et al., 2011; PedrozaGonzalez et al., 2011) . The relevance of TSLP in this respect is indeed highlighted by the fact that pharmaceutical companies are seeking to develop drugs directed against TSLP (Edwards, 2008) . However, within the human population, individuals who suffer from atopic allergic disorders have a reduced risk of developing certain types of cancer (Gandini et al., 2005; Prizment et al., 2007; Vajdic et al., 2009; Wang and Diepgen, 2005) . It is tempting to speculate that the context in which TSLP functions as a tumor suppressor or tumor promoter is related to how allergic immune responses affect barrier versus glandular epithelial cells. It will be interesting to determine if TSLP-responsive T cells that induce allergic inflammation in other barrier epithelia, such as lung (Al-Shami et al., 2005) , are also tumor protective. Thus, whether TSLP is inducing a pro-or antitumorigenic immune response appears to be context-and tissue-dependent, and therefore blocking TSLP-mediated responses as a potential cancer treatment is a hypothesis that must be analyzed with caution.
EXPERIMENTAL PROCEDURES Ethics Statement
All animal work was conducted in accordance with Swiss national guidelines. All mice were kept in the animal facility under EPFL animal care regulations. They were housed in individual cages at 23 C ± 1 C with a 12 hr light/dark cycle. All animals were supplied with food and water ad libitum. This study has been reviewed and approved by the Service Vé té rinaire Cantonal of Etat de Vaud. (Malanchi et al., 2008) (Harada et al., 1999) were crossed with Tslpr À/À mice and K5Cre ERT transgenic mice (Indra et al., 1999) /J) mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). All mice used as donors in the bone marrow chimera and adoptive transfer experiments were on a pure C57BL/6 background. All Notch mutants were backcrossed >10 generations with C57BL/6 mice and thus can be considered to be on a pure C57BL/6 background. Depending on the experiment, gene inactivation was achieved by intraperitoneal injection at P6, P30, or P60 of control and floxed mutant mice with 1 mg/20 g body weight of tamoxifen (Sigma-Aldrich, St. Gallen, Switzerland) for five consecutive days.
Dermal Cell Isolation
Back skin was aseptically dissected from mice and incubated dermis-side down in a 1 mg/ml solution of collagenase/dispase (Roche, Indianapolis, IN, USA) for 1 hr at 37 C. The dermis was separated from the epidermis, dissociated mechanically, and incubated in a 2 mg/ml solution of collagenase (Sigma-Aldrich) for 45 min at 37 C with gentle agitation. Cell suspensions were filtered through a 70 mm cell strainer (BD Falcon, Franklin Lakes, NJ, USA) and washed twice in staining medium (13 HBSS/25 mM HEPES/2% newborn bovine calf serum).
Flow Cytometry
Single-cell suspensions were stained with monoclonal antibody conjugates in accordance with standard protocols and analyzed using a CyAn flow cytometer (Dako, Glostrup, Denmark). Data analysis and processing was performed using FlowJo software (Tree Star, Ashland, OR, USA).
Immunohistochemistry and Immunofluorescence
For immunohistochemistry, tissues were fixed in 4% PFA and embedded in paraffin. After sectioning, 4 mm sections were rehydrated, blocked with 3% H 2 O 2 , and incubated in antigen retrieval buffer (10 mM Tris/1 mM EDTA/0.05% Tween 20 [pH 9.0]) at 95 C for 20 min. Sections were then stained using unconjugated primary antibodies and the appropriate HRPconjugated secondary antibodies. Staining was revealed by DAB (SigmaAldrich) revelation. For immunofluorescence, tissues were embedded in OCT compound and frozen. Cryosections (8 mm) were then fixed in acetone at 4 C for 2 min and air-dried for 20 min. After rinsing in PBS, sections were stained with unconjugated primary antibodies and the appropriate fluorophore-conjugated secondary antibodies. Fluorescent images were acquired using an LSM700 confocal microscope (Zeiss, Oberkochen, Germany 
